Basics Editas Medicine, Inc. Editas Medicine Inc is a genome editing company which is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. IPO Date: February 3, 2016 Sector: Healthcare Industry: Biotech Market Cap: $230.21M Activated in VL: True Average Daily Range Avg Daily Range: $0.72 | 3.36% Avg Daily Range (30 D): $0.12 | 4.93% Avg Daily Range (90 D): $0.08 | 4.68% Institutional Daily Volume Avg Daily Volume: 1.26M Avg Daily Volume (30 D): 2.87M Avg Daily Volume (90 D): 2.13M Trade Size Avg Trade Size (Sh.): 108 Avg Trade Size (Sh.) (30 D): 240 Avg Trade Size (Sh.) (90 D): 253 Institutional Trades Total Inst.Trades: 3,799 Avg Inst. Trade: $2M Avg Inst. Trade (30 D): $1.39M Avg Inst. Trade (90 D): $1.09M Avg Inst. Trade Volume: .1M Avg Inst. Trades (Per Day): 2 Market Closing Trades Avg Closing Trade: $2.79M Avg Closing Trade (30 D): $1.65M Avg Closing Trade (90 D): $1.17M Avg Closing Volume: 160.4K     News Jun 27, 2025 @ 12:15 PM 2 Beaten-Down Stocks to Avoid Source: Prosper Junior Bakiny Jun 17, 2025 @ 2:07 PM Editas Medicine Is Great. Here's Why You Shouldn't... Source: Dan Victor Jun 12, 2025 @ 6:01 AM Editas Medicine Reports Proprietary Targeted Lipid... Source: Editas Medicine Mar 6, 2025 @ 6:00 PM Global Genome Editing Market to Grow Rapidly at a ... Source: Delveinsight Feb 21, 2025 @ 6:00 PM Cell and Gene Therapies in Rare Disorders Market t... Source: Delveinsight Financials   TTM Q1 2025 Q4 2024 Basic EPS $-3.04 $-.92 $-.55 Diluted EPS $-3.04 $-.92 $-.55 Revenue $ 35.84M $ 4.66M $ 30.6M Gross Profit $ $ $ Net Income / Loss $ -251.23M $ -76.09M $ -45.4M Operating Income / Loss $ -260.33M $ -76.16M $ -46.59M Cost of Revenue $ $ $ Net Cash Flow $ 69.47M $ 7.15M $ 35.71M PE Ratio